Wednesday, February 10, 2010, 7:38pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Peregrine Pharmaceuticals Inc. (PPHMD)

On Nov 14: 3.15 USD   0.00 (0.00%)  
 MORE ON PPHMD 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Peregrine Pharmaceuticals Inc. (NCM:PPHMD) Delayed quote dataEdit
Last Trade:3.15 USD
Trade Time:Nov 14
Change: 0.00 (0.00%)
Prev Close:3.15
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:N/A
Day's Range:N/A - N/A
52wk Range:N/A
Volume:0
Avg Vol (3m):N/A
Market Cap:N/A
P/E (ttm):N/A
EPS (ttm):N/A
Div & Yield: (N/A%)
[Chart]
1d  5d
Use Y! Toolbar to track stocks
 Add PPHMD to Portfolio   Download Data

 HEADLINES 
•PEREGRINE PHARMACEUTICALS INC Financials
EDGAR Online Financials (Thu, Dec 17)
•Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference - In Preclinical
PRNewswire (Wed, Nov 18)
•UBS Research Equity Analyst Picks Top Stocks In Large Cap Biotech Sector
Wall Street Transcript (Wed, Nov 11)
•New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model - Treatment
PRNewswire (Tue, Nov 10)
•Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies --Broad New Patent Covers
PRNewswire (Thu, Nov 5)
•Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
PRNewswire (Wed, Nov 4)
•Biotech Sector Pullback: Good Time to Buy at a Discount
at Seeking Alpha (Thu, Oct 29)
•PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits
EDGAR Online (Tue, Oct 27)
•PEREGRINE PHARMACEUTICALS INC Financials
EDGAR Online Financials (Thu, Oct 22)
•Peregrine drug prompts response in cancer study
AP (Thu, Oct 22)
•Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer - 28 of 46 (61%) Pat
PRNewswire (Wed, Oct 21)
More Headlines for PPHMD...
 BUSINESS SUMMARY 
No business summary available for PPHMD.


Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices